Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eltrombopag for secondary immune thrombocytopenia in chronic lymphoproliferative disorders
2011-004657-11Phase 2Active
- Sponsor
- Fondazione Progetto Ematologia
- Start
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eltrombopag in immune thrombocytopenia (ITP) and lymphoproliferative disorder (LPD), sponsored by Fondazione Progetto Ematologia. Primary endpoint: Primary efficacy endpoint. Started Aug 2012; status: active.
02
Drugs
eltrombopag
03
Conditions
immune thrombocytopenia (ITP)lymphoproliferative disorder (LPD)
Beyond the preview
Go deeper on 2011-004657-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004657-11.